Oct. 09, 2025 4:13 AM ETBoston Scientific Corporation (BSX) StockELUT, BSXThe Alpha Sieve4.65K FollowersSummaryBoston Scientific, which was faring relatively well over the first 8 months of the year, appears to have lost its footing of late and is now trading below all its key moving averages.The upcoming Q3 earnings event due to be held on the 22nd of October could play a key role in dictating the next course of action.BSX may likely beat consensus on the topline and bottomline, but the pace of underlying organic growth will continue to decline, and gross margins too will face continued pressure.The recent BioEnvelope acquisition does raise a few question marks, given that the acquired portfolio will be a part of BSX's slowest-growing market- Cardiac Rhythm Management Diagnostics.At 32x forward P/E BSX is hardly cheap, more so in light of the medium-term earnings growth on offer, and it also remains one of the most overbought stocks within the large-cap healthcare space.Shinsei Motions/iStock via Getty ImagesA Mixed 2025 So Far, Depending On Which Comparative Lens You Look AtThe mega-cap stock of Boston Scientific Corporation (NYSE:BSX), one of the prominent providers of medical devices, particularly in the cardiovascular space, hasThis article was written byThe Alpha Sieve4.65K FollowersInvestment research, primarily oriented towards uncelebrated/under-covered stocks and ETFs, across North America, Latin America, Europe and Asia. Seeks to combine both fundamental and technical disciplines while making an investment/trading proposition.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments